Non-albicans candida species in blood stream infections in a tertiary care hospital at New Delhi, India

Indian Journal of Medical Research

Volumn 136, Issue 6, 2012, Pages 997-1003

  Oberoi, Jaswinder Kaur ^a   Wattal, Chand ^a   Goel, Neeraj ^a   Raveendran, Reena ^a   Datta, S ^a   Prasad, Kamaljeet ^a  

^a SIR GANGA RAM HOSPITAL   (India)

Author keywords

Antifungal use; Candida haemulonii; Candidaemia; Fuconazole; Non albicans candida species

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BROTH DILUTION; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA HAEMULONII; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA RUGOSA; CANDIDA TROPICALIS; CANDIDEMIA; HUMAN; INCIDENCE; INDIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; PICHIA ANOMALA; PREDICTIVE VALUE; RETROSPECTIVE STUDY; TERTIARY HEALTH CARE; BLOOD; CANDIDIASIS; CROSS INFECTION; DRUG EFFECTS; GENETICS; MICROBIAL SENSITIVITY TEST; PROCEDURES; STATISTICS AND NUMERICAL DATA; TERTIARY CARE CENTER;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; CROSS INFECTION; FLUCONAZOLE; FLUCYTOSINE; HUMANS; INCIDENCE; INDIA; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; RETROSPECTIVE STUDIES; TERTIARY CARE CENTERS; TRIAZOLES; VORICONAZOLE;

EID: 84873173189     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-17.
2. Marchetti O, Bille J, Fluckiger U, Eggimann P, Ruef C, Garbino J, et al. Epidemiology of candidaemia in Swiss tertiary care hospitals: Secular trends, 1991-2000. Clin Infect Dis 2004; 38: 311-20.
3. Lark RL, Chenoweth C, Saint S, Zemencuk JK, Lipsky BA, Plorde JJ. Four year prospective evaluation of nosocomial bacteremia: epidemiology, microbiology, and patient outcome. Diagn Microbiol Infect Dis 2000; 38: 131-40.
4. Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, et al. Attributable mortality of nosocomial candidaemia, revisited. Clin Infect Dis 2003; 37: 1172-7.
5. Krcmery V, Barnes AJ. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J Hosp Infect 2002; 50: 243-60.
6. Magill SS, Shields C, Sears CL, Choti M, Merz WG. Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy. J Clin Microbiol 2006; 44: 529-35.
7. Xess I, Jain N, Hasan F, Mandal P, Banerjee U. Epidemiology of candidemia in a tertiary care centre of north India: 5-year study. Infection 2007; 35: 256-9.
8. Kothari A, Sagar V. Epidemiology of candida bloodstream infections in a tertiary care institute in India. Indian J Med Microbiol 2009; 27: 171-2.
9. Shivaprakasha S, Radhakrishnan K, Karim PM. Candida spp. other than Candida albicans: a major cause of fungaemia in a tertiary care centre. Indian J Med Microbiol 2007; 25: 405-7.
10. Chakrabarti A, Chatterjee SS, Rao KL, Zameer MM, Shivaprakash MR, Singhi S, et al. Recent experience with fungaemia: change in species distribution and azole resistance. Scand J Infect Dis 2009; 41: 275-84.
11. nd ed. National Committee for Clinical Laboratory Standards, Wayne, PA; 2002.
12. González GM, Elizondo M, Ayala J. Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) surveillance study. J Clin Microbiol 2008; 46: 2902-5.
13. Nguyen MH, Clancy CJ, Yu VL, Yu YC, Morris AJ, Snydman DR, et al. Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. J Infect Dis 1998; 177: 425-30.
14. rd ed. Wayne, PA: CLSI; 2008.
15. Pfaller MA, Diekema DJ, Rex JH, Espinel-Ingroff A, Johnson EM, Andes D, et al. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol 2006; 44: 819-26.
16. de With K, Steib-Bauert MS, Knoth H, Dorje F, Strehl E, Rothe U, et al. Hospital use of antifungal drugs. BMC Clin Pharmacol 2005; 10: 1.
17. World Health Organization. The anatomical therapeutic chemical classifcation system with defned daily doses (ATC/ DDD). Norway: WHO, 2004. Available from: http://www.who.int/classifcations/atcddd/en/, accessed on February 16, 2009.
18. Sendid B, Cotteau A, François N, D'Haveloose A, Standaert A, Camus D, et al. Candidaemia and antifungal therapy in a French University Hospital: rough trends over a decade and possible links. BMC Infect Dis 2006; 6: 80.
19. Banerjee SN, Emori TG, Culver DH, Gaynes RP, Jarvis WR, Horan T, et al. Secular trends in nosocomial primary bloodstream infections in the United States. Am J Med 1991; 91: 86S-89S.
20. Chakrabarti A, Chander J, Kasturi P, Panigrahi D. Candidemia: a 10-year study in an Indian teaching hospital. Mycoses 1992; 35: 47-51.
21. Chakrabarti A, Ghosh A, Batra R, Kaushal A, Roy P, Singh H. Antifungal susceptibility pattern of non-albicans candida species and distribution of species isolated from candidaemia cases over a 5-year period. Indian J Med Res 1996; 104: 171-6.
22. Goel N, Wattal C, Oberoi JK, Raveendran R, Datta S, Prasad KJ. Trend analysis of antimicrobial consumption and development of resistance in non- fermenters in a tertiary care hospital in Delhi, India. J Antimicrob Chemother 2011; 66: 1625-30.
23. Presterl E, Daxböck F, Graninger W, Willinger B. Changing pattern of candidaemia 2001-2006 and use of antifungal therapy at the University Hospital of Vienna, Austria. Clin Microbiol Infect 2007; 13: 1072-6.
24. Khan ZU, Al-Sweih NA, Ahmad S, Al-Kazemi N, Khan S, Joseph L, et al. An outbreak of fungaemia among neonates caused by Candida haemulonii resistant to Amphotericin B, Itraconazole and Fluconazole. J Clin Microbiol 2007; 45: 2025-7.
25. Ruan SY, Kuo YW, Huang CT, Hsiue HC, Hsueh PR. Infections due to Candida haemulonii: species identifcation, antifungal susceptibility and outcomes. Int J Antimicrob Agents 2010; 35: 85-8.
26. Kim MN, Shin JH, Sung H, Lee K, Kim EC, Ryoo N, et al. Candida haemulonii and closely related species at 5 university hospitals in Korea: identifcation, antifungal susceptibility, and clinical features. Clin Infect Dis 2009; 48: e57-61.
27. Odds FC, Hanson MF, Davidson AD, Jacobsen MD, Wright P, Whyte JA, et al. One year prospective survey of Candida bloodstream infections in Scotland. J Med Microbiol 2007; 56: 1066-75.
28. Tan TY, Tan AL, Tee NW, Ng LS. A retrospective analysis of antifungal susceptibilities of Candida bloodstream isolates from Singapore hospitals. Ann Acad Med Singapore 2008; 37: 835-40.
29. Sarvikivi E, Lyytikäinen O, Soll DR, Pujol C, Pfaller MA, Richardson M, et al. Emergence of fuconazole resistance in a Candida parapsilosis strain that caused infections in a neonatal intensive care unit. J Clin Microbiol 2005; 43: 2729-35.
30. Yoder BA, Sutton DA, Winter V, Coalson JJ. Resistant Candida parapsilosis associated with long term fuconazole prophylaxis in an animal model. Pediatr Infect Dis J 2004; 23: 687-8.
31. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Ellis D, Tullio V, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-Year analysis of susceptibilities of Candida species to fuconazole and voriconazole determined by CLSI Standardized Disk Diffusion. J Clin Microbiol 2010; 48: 1366-77.